Gastrointestinal Stromal Tumor Clinical Trial
Official title:
A Prospective, Single-arm, Multi-center Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in RefrActory MetAstatic Gastrointestinal Stromal Tumor
The purpose of this study is to determine whether dasatinib is effective and safe in the treatment of refractory metastatic gastrointestinal stromal tumor
Status | Recruiting |
Enrollment | 57 |
Est. completion date | May 2018 |
Est. primary completion date | October 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed recurrent/metastatic gastrointestinal stromal tumor (GIST). Immunohistochemically, the detection KIT and/or DOG-1 are/is positive - Patients must have measurable disease meeting the requirement of RECIST 1.1 - Received the gene mutation detection of c - kit/PDGFRA - Subjects with mutation in exon 11, in exon 9 and wild type c-kit/PDGFRA have failed to imatinib and sunitinib - Subjects with primary mutation in exon 17 or 18 have failed to imatinib - Subjects with primary mutation in exon 11 and secondary mutation in exon 17 or 18 have failed to imatinib - Subjects with mutation in exon 18 of PDGFRA,have received TKI or not - Eastern Cooperative Oncology Group (ECOG) performance status = 0-2 - Expected OS =3 months - Ability to understand and the willingness to sign a written informed consent document - Subject will comply with the study procedures and therapy Exclusion Criteria: - Local or metastatic GIST is resectable - Unable to receive the gene mutation detection of c-kit (c-kitproto-oncogeneprotein)/PDGFRA - AST and/or ALT > 2.5 times ULN, or Bilirubin >1.5 times upper limit of normal (ULN) - Neutrophil count < 1.5 x 10^9/L, or Platelet count <75 x 10^9/L, or Hemoglobin<90g/L - Cr >1.5×ULN - Other malignancy within the past 5 years except for adequately treated carcinoma in situ of the cervix or cutaneous basal cell carcinoma - Known brain metastasis, spinal cord compression, carcinomatous meningitis, or cerebral or soft meningeal disease through CT or MRI during screening stage - Within the past 5 years, subjects have one of the following disease: myocardial infarction, serious/instable angina pectoris, symptomatic congestive heart failure or cerebrovascular accident from coronary/peripheral artery bypass grafting - Known human immunodeficiency virus positivity - Joining in other trail - Women who are pregnant or lactating; No contraception for subject during childbearing period - Subject with other serious acute and chronic physical or mental problems, or laboratory abnormality, will increase the risks associated with trail or drug. It will also interference the judgment of the results. In the judgment of the investigator, subject is inadequate to participant the study |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Chinese PLA General Hospital | Beijing | Beijing |
China | West China Hospital , Sichuan University | Chengdu | Sichuan |
China | The First Affiliated Hospital,Sun Yat-sen University | Guangzhou | Guangdong |
China | No.81 Hospital of Chinese People's Liberation Army | Nanjing | Jiangsu |
China | Fudan University Shanghai Cancer Center | Shanghai | Shanghai |
China | Shanxi Cancer Hospital | Taiyuan | Shanxi |
Lead Sponsor | Collaborator |
---|---|
Beijing Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survive, calculated from registration until progression or death | 2 years | No | |
Secondary | Overall survival, overall survival will be calculated from registration until death | 2 years | No | |
Secondary | Adverse drug reactions according to NCI CTCAE v4.0 | 2 years, Tolerability will be assessed based on the frequency and severity of Adverse Drug Reactions (ADR) coded according to NCI CTCAE v4.0. | Yes | |
Secondary | Objective response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria | 2 years | No | |
Secondary | Tumor control probability, defined as CR+PR+SD, determined according to RECIST 1.1 criteria | 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04933669 -
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
|
Phase 2 | |
Completed |
NCT01769248 -
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
|
N/A | |
Completed |
NCT01774162 -
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
|
N/A | |
Completed |
NCT01110668 -
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Terminated |
NCT00091078 -
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00025246 -
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
|
Phase 2 | |
Active, not recruiting |
NCT00265798 -
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
|
Phase 2 | |
Recruiting |
NCT04143048 -
A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
|
||
Recruiting |
NCT02931981 -
Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
|
N/A | |
Not yet recruiting |
NCT02576080 -
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
|
Phase 3 | |
Recruiting |
NCT01389583 -
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
|
Phase 2 | |
Recruiting |
NCT00777504 -
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
|
Phase 4 | |
Completed |
NCT00769782 -
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00764595 -
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00098579 -
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00005862 -
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01751919 -
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
|
Phase 1 | |
Completed |
NCT01267695 -
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
|
Phase 2 | |
Terminated |
NCT00956072 -
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
|
Phase 3 |